Novogen's NV-128 Is a Unique Inhibitor of mTOR Dephosphorylation Leading to Caspase Independent Death in Chemoresistant Cancer C
April 15 2008 - 5:25PM
Marketwired
SAN DIEGO, CA and phenoxodiol, both of which are investigational
drugs that have been licensed by Novogen to Marshall Edwards, Inc.
Phenoxodiol is currently in a multinational, multi-center Phase III
clinical trial for patients with late stage ovarian cancer.
Triphendiol has recently been granted orphan drug status by the FDA
for pancreatic and bile duct cancers, and late stage melanoma.
"The ability of our suite of analogues to invoke discreet modes
of cell death suggests that they have potential to be used
synergistically, thereby inhibiting alternative modes of cancer
cell survival which may be invoked post therapy. This could lower
the incidence of residual disease clinically," said Professor Alan
Husband, Group Director of Research, Novogen, Ltd.
Unlike analogues of rapamycin, like temsirolimus and everolimus,
which target only mTORC1, NV-128's capacity to dephosphorylate mTOR
enables it to inhibit both mTORC1 and mTORC2 activity. This blocks
growth factor driven activation of AKT and the potential for
development of chemoresistance. Further, unlike NV-128, rapalogs
invoke caspase-mediated apoptosis making them less effective in
those cancer cells that have developed rapalog-resistance and have
a dysfunctional apoptotic cascade.
Also presented in Dr. Alvero's paper was a proof of concept
study in an animal model of drug resistant ovarian cancer, where it
has been demonstrated that NV-128 not only significantly retards
tumor proliferation, but is more efficacious than other standard of
care drugs. It was also reported that phosphorylated p70s6K was
decreased, and endonucelase G was increased in tumors taken from
mice dosed with NV-128 thereby confirming that the NV-128 mechanism
of action in vivo is the same as that observed in vitro, and that
both proteins can be employed as markers of NV-128 efficacy.
"We are just now beginning to realize the depth of oncology drug
candidates that our technology will uncover," said Professor
Husband. "We anticipate that refinement of our proprietary
molecular scaffold driven by computer-based molecular modeling,
will continue to yield novel derivatives not only indicated as
oncology leads, but also for cardiovascular and inflammatory
diseases."
About NV-128:
In contrast to phenoxodiol and triphendiol, NV-128 has been
shown to induce caspase-independent DNA degradation and cancer cell
death. It appears that in conjunction with autophagy induction,
NV-128 induces caspase independent cell death via the AKT-mTOR
pathway resulting in beclin sequestration of Bcl-2, Bax
up-regulation and mitochondrial depolarization. As a consequence,
endonuclease G translocates to the nucleus where it initiates DNA
degradation and cell death. This offers an opportunity for use as a
monotherapy in chemoresistant cancers and enhanced efficacy against
cancer targets less susceptible to phenoxodiol. The option for
co-administration of combinations of these drugs is also under
investigation to extend the potential therapeutic range of this
unique class of oncology compounds.
About Novogen Limited:
Novogen Limited (ASX: NRT) (NASDAQ: NVGN) is an Australian
biotechnology company that has patented isoflavone technology for
the treatment and prevention of degenerative diseases and
disorders. Over the past ten years, Novogen has conducted the
largest and most comprehensive isoflavone clinical testing programs
in the world. Novogen is involved in drug discovery and product
development for a range of degenerative disorders including cancer,
cardiovascular diseases and inflammatory diseases. The Company
coordinates an international clinical research and development
program with external collaborators, hospitals and universities.
For more information, visit www.novogen.com.
Under U.S. law, a new drug cannot be marketed until it has been
investigated in clinical trials and approved by the FDA as being
safe and effective for the intended use. Statements included in
this press release that are not historical in nature are
"forward-looking statements" within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ
materially from those contained in the forward-looking statements,
which are based on management's current expectations and are
subject to a number of risks and uncertainties, including, but not
limited to, our failure to successfully commercialize our product
candidates; costs and delays in the development and/or FDA
approval, or the failure to obtain such approval, of our product
candidates; uncertainties in clinical trial results; our inability
to maintain or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization,
marketing, sales and distribution of any products; competitive
factors; our inability to protect our patents or proprietary rights
and obtain necessary rights to third party patents and intellectual
property to operate our business; our inability to operate our
business without infringing the patents and proprietary rights of
others; general economic conditions; the failure of any products to
gain market acceptance; our inability to obtain any additional
required financing; technological changes; government regulation;
changes in industry practice; and one-time events. We do not intend
to update any of these factors or to publicly announce the results
of any revisions to these forward-looking statements.
Contacts: David Sheon 202 422-6999 Email Contact Chris Naughton
011 61 2 9878 0088 Email Contact
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024